← Back to Search

Behavioral Nudge for Genetic Predisposition

N/A

Recruiting

Led By Katherine L Nathanson, MD

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age or older

diagnosed with one of the study conditions

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to find new ways to deliver genetic testing results that can change medical management beyond traditional genetic counseling visits. The study will use non-geneticist clinicians and patient nudges in a randomized clinical

Who is the study for?

Adults diagnosed with specific conditions like Alzheimer's, various heart diseases, and genetic predispositions that can change medical management based on genetic testing results. Participants must be over 18 years old.

What is being tested?

The trial is testing a new approach to genomic medicine using electronic health records (EHR) to nudge clinicians and patients towards the use of genetic testing. It involves direct test ordering, EHR algorithms for patient identification, and behavioral economics methods.

What are the potential side effects?

Since this trial focuses on behavioral nudges rather than medications or invasive procedures, traditional physical side effects are not expected. However, there may be psychological impacts or changes in healthcare decisions due to the nudging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with a condition being studied.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Rate of Genetic Testing

Secondary study objectives

Rate of Clinician actions

Rate of Genetic Test Orders/Referrals

Rate of Pathogenic variants and VUS

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups

Active Control

Group I: Clinician BPA refer plus patient nudgeActive Control1 Intervention

Clinician will receive a nudge to refer patient for genetic testing and the patient will receive a text message encouraging them to speak with their clinician about genetic testing.

Group II: Clinician nudge, referActive Control1 Intervention

Clinician will receive a nudge to refer the patient for genetic testing.

Group III: Generic BPA; no nudgeActive Control1 Intervention

Usual care

Group IV: Clinician nudge, orderActive Control1 Intervention

Clinician will receive a nudge to order genetic testing for the patient.

Group V: Patient nudgeActive Control1 Intervention

The patient will receive a text message encouraging them to speak with their clinician about genetic testing.

Group VI: Clinician BPA order plus patient nudgeActive Control1 Intervention

Clinician will receive a nudge to order genetic testing for the patient and the patient will receive a text message encouraging them to speak with their clinician about genetic testing.

0 / 2Eligibility criteria met